



US008853260B2

(12) **United States Patent**
Desai et al.

(10) **Patent No.:** US 8,853,260 B2
(45) **Date of Patent:** Oct. 7, 2014

(54) **FORMULATIONS OF PHARMACOLOGICAL AGENTS, METHODS FOR THE PREPARATION THEREOF AND METHODS FOR THE USE THEREOF**

(75) Inventors: **Neil P. Desai**, Santa Monica, CA (US); **Patrick Soon-Shiong**, Los Angeles, CA (US)

(73) Assignee: **Abraxis BioScience, LLC**, Los Angeles, CA (US)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 1070 days.

(21) Appl. No.: **11/520,479**

(22) Filed: **Sep. 12, 2006**

(65) **Prior Publication Data**

US 2007/0093547 A1 Apr. 26, 2007

Related U.S. Application Data

(63) Continuation of application No. 09/446,783, filed as application No. PCT/US98/13272 on Jun. 26, 1998, and a continuation-in-part of application No. 08/926,155, filed on Sep. 9, 1997, now Pat. No. 6,096,331.

(60) Provisional application No. 60/051,021, filed on Jun. 27, 1997.

(51) **Int. Cl.**

A01N 43/02 (2006.01)
A01N 25/00 (2006.01)
A61K 31/335 (2006.01)
A61K 47/00 (2006.01)

(52) **U.S. Cl.**

USPC **514/449; 514/776**

(58) **Field of Classification Search**

None

See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

4,452,817 A 6/1984 Glen et al.
4,534,899 A 8/1985 Sears

(Continued)

FOREIGN PATENT DOCUMENTS

CN 1148957 A 5/1997
EP 0 326 618 A1 8/1989

(Continued)

OTHER PUBLICATIONS

Vippagunta et al (Vippagunta et al. Crystalline solids. Advanced Drug Delivery Reviews. 2001;48:3-26.*

(Continued)


Primary Examiner — Trevor Love

(74) Attorney, Agent, or Firm — Morrison & Foerster LLP

(57) **ABSTRACT**

In accordance with the present invention, there are provided compositions and methods useful for the in vivo delivery of substantially water insoluble pharmacologically active agents (such as the anticancer drug paclitaxel) in which the pharmacologically active agent is delivered in the form of suspended particles coated with protein (which acts as a stabilizing agent). In particular, protein and pharmacologically active agent in a biocompatible dispersing medium are subjected to high shear, in the absence of any conventional surfactants, and also in the absence of any polymeric core material for the particles. The procedure yields particles with a diameter of less than about 1 micron. The use of specific composition and preparation conditions (e.g., addition of a polar solvent to the organic phase), and careful selection of the proper organic phase and phase fraction, enables the reproducible production of unusually small nanoparticles of less than 200 nm diameter, which can be sterile-filtered. The particulate system produced according to the invention can be converted into a redispersible dry powder comprising nanoparticles of water-insoluble drug coated with a protein, and free protein to which molecules of the pharmacological agent are bound. This results in a unique delivery system, in which part of the pharmacologically active agent is readily bioavailable (in the form of molecules bound to the protein), and part of the agent is present within particles without any polymeric matrix therein.

27 Claims, 4 Drawing Sheets



(56)

References Cited**U.S. PATENT DOCUMENTS**

4,693,367 A	9/1987	Mathieu	6,743,826 B1	6/2004	Hegedus et al.
4,798,846 A	1/1989	Glen et al.	6,749,868 B1	6/2004	Desai et al.
4,963,367 A	10/1990	Ecanow	6,753,006 B1	6/2004	Desai et al.
5,059,699 A	10/1991	Kingston et al.	6,759,431 B2	7/2004	Hunter et al.
5,069,936 A	12/1991	Yen	7,238,369 B2	7/2007	McDonald et al.
5,362,478 A	11/1994	Desai et al.	7,332,568 B2	2/2008	Trieu et al.
5,362,831 A	11/1994	Mongelli	8,138,229 B2	3/2012	Desai et al.
5,399,363 A	3/1995	Liversidge et al.	8,257,733 B2	9/2012	Desai et al.
5,407,683 A *	4/1995	Shively	8,268,348 B2	9/2012	Desai et al.
5,415,869 A	5/1995	Straubinger et al.	8,314,156 B2	11/2012	Desai et al.
5,424,073 A	6/1995	Rahman et al.	2003/0054042 A1	3/2003	Liversidge et al.
5,439,686 A	8/1995	Desai et al.	2003/0087985 A1	5/2003	Hubbell et al.
5,498,421 A	3/1996	Grinstaff et al.	2003/0199425 A1	10/2003	Desai et al.
5,505,932 A	4/1996	Grinstaff et al.	2005/0004002 A1	1/2005	Desai et al.
5,508,021 A	4/1996	Grinstaff et al.	2006/0083782 A1	4/2006	Desai et al.
5,512,268 A	4/1996	Grinstaff et al.	2006/0121119 A1	6/2006	Zenoni et al.
5,560,933 A	10/1996	Soon-Shiong et al.	2006/0210638 A1	9/2006	Liversidge et al.
5,565,478 A	10/1996	Kohn et al.	2006/0257326 A1	11/2006	Desai et al.
5,567,434 A	10/1996	Szoka, Jr.	2006/0263434 A1	11/2006	Desai et al.
5,616,330 A *	4/1997	Kaufman et al.	2007/0020337 A1	1/2007	Zenoni et al.
5,616,608 A	4/1997	Kinsella et al.	2007/0082838 A1	4/2007	De et al.
5,626,862 A	5/1997	Brem et al.	2007/0087022 A1	4/2007	Desai et al.
5,626,867 A	5/1997	Eibl et al.	2007/0092563 A1	4/2007	Desai et al.
5,635,207 A	6/1997	Grinstaff et al.	2007/0116774 A1	5/2007	Desai et al.
5,639,473 A	6/1997	Grinstaff et al.	2007/0117133 A1	5/2007	Trieu et al.
5,648,090 A	7/1997	Rahman et al.	2007/0117744 A1	5/2007	Desai et al.
5,650,156 A	7/1997	Grinstaff et al.	2007/0117862 A1	5/2007	Desai et al.
5,651,986 A	7/1997	Brem et al.	2007/0117863 A1	5/2007	Desai et al.
5,665,382 A	9/1997	Grinstaff et al.	2007/0128290 A1	6/2007	Desai et al.
5,665,383 A	9/1997	Grinstaff et al.	2007/0129448 A1	6/2007	Desai et al.
5,670,536 A	9/1997	Durr et al.	2007/0166388 A1	7/2007	Desai et al.
5,681,846 A *	10/1997	Trissel	2007/0196361 A1	8/2007	Soon-Shiong et al.
5,683,715 A	11/1997	Boni et al.	2008/0063724 A1	3/2008	Desai et al.
5,703,117 A	12/1997	Mayhew et al.	2008/0153738 A1	6/2008	Desai et al.
5,716,981 A	2/1998	Hunter et al.	2008/0153739 A1	6/2008	Desai et al.
5,725,804 A *	3/1998	Yen	2008/0160095 A1	7/2008	Desai et al.
5,731,334 A	3/1998	Wrasidlo	2008/0161382 A1	7/2008	Desai et al.
5,733,925 A	3/1998	Kunz et al.	2008/0166389 A1	7/2008	Desai et al.
5,756,537 A	5/1998	Gill	2008/0280987 A1	11/2008	Desai et al.
5,766,635 A	6/1998	Spenleuhauer et al.	2009/0098210 A1	4/2009	Desai et al.
5,795,909 A	8/1998	Shashoua et al.	2009/0175951 A1	7/2009	Liversidge
5,811,447 A	9/1998	Kunz et al.	2009/0196933 A1	8/2009	Desai et al.
5,886,026 A	3/1999	Hunter et al.	2009/0263483 A1	10/2009	Desai et al.
5,916,596 A *	6/1999	Desai et al.	2009/0304805 A1	12/2009	Desai et al.
5,928,669 A	7/1999	Davis et al.	2010/0035800 A1	2/2010	Desai et al.
5,945,033 A	8/1999	Yen	2010/0048499 A1	2/2010	Desai et al.
5,977,163 A *	11/1999	Li et al.	2010/0112077 A1	5/2010	Desai et al.
5,981,568 A	11/1999	Kunz et al.	2010/0166869 A1	7/2010	Desai et al.
5,994,341 A	11/1999	Hunter et al.	2010/0183728 A1	7/2010	Desai et al.
5,997,904 A	12/1999	Magdassi et al.	2010/0196490 A1	8/2010	Desai et al.
6,051,600 A	4/2000	Mayhew et al.	2010/0215751 A1	8/2010	Desai et al.
6,066,668 A	5/2000	Hausheer et al.	2010/0226996 A1	9/2010	Desai et al.
6,074,659 A	6/2000	Kunz et al.	2010/0297243 A1	11/2010	Desai et al.
6,096,331 A	8/2000	Desai et al.	2011/0052708 A1	3/2011	Soon-Shiong et al.
6,107,332 A	8/2000	Ali et al.	2011/0064812 A1	3/2011	Bahl et al.
6,120,805 A	9/2000	Spenleuhauer et al.	2011/0118342 A1	5/2011	De et al.
6,143,276 A	11/2000	Unger	2011/0231082 A1	6/2011	Desai et al.
6,146,659 A	11/2000	Rahman	2012/0004177 A1	1/2012	Desai et al.
6,146,663 A	11/2000	Bissery et al.	2012/0070502 A1	3/2012	Desai et al.
6,179,817 B1	1/2001	Zhong	2012/0076862 A1	3/2012	Desai et al.
6,197,051 B1	3/2001	Zhong	2012/0128732 A1	5/2012	Trieu et al.
6,197,349 B1	3/2001	Westesen et al.	2012/0189701 A1	7/2012	Desai et al.
6,268,390 B1	7/2001	Kunz	2012/0231082 A1	9/2012	Desai et al.
6,306,421 B1	10/2001	Kunz et al.	2012/0283205 A1	11/2012	Desai et al.
6,322,805 B1	11/2001	Kim et al.	2012/0308612 A1	12/2012	De et al.
6,432,928 B1	8/2002	Szente et al.	2013/0045240 A1	2/2013	Tao et al.
6,441,025 B2	8/2002	Li et al.	2013/0071438 A1	3/2013	Desai et al.
6,458,373 B1	10/2002	Lambert et al.	2013/0115296 A1	5/2013	Yeo et al.
6,500,461 B2	12/2002	Perkins et al.	2013/0195922 A1	8/2013	Desai et al.
6,506,405 B1	1/2003	Desai et al.	2013/0195983 A1	8/2013	Desai et al.
6,528,067 B1	3/2003	Magdassi et al.	2013/0195984 A1	8/2013	Desai et al.
6,537,579 B1	3/2003	Desai et al.	2013/0202709 A1	8/2013	Desai et al.
6,565,842 B1	5/2003	Sojomihardio et al.	2013/0202709 A1	8/2013	Desai et al.

(56)

References Cited

U.S. PATENT DOCUMENTS

- 2013/0266659 A1 10/2013 Desai et al.
 2013/0280336 A1 10/2013 Desai et al.
 2013/0280337 A1 10/2013 Desai et al.

FOREIGN PATENT DOCUMENTS

- JP 63-502117 A 8/1988
 WO WO-87/04592 A1 8/1987
 WO WO-93/24476 A1 12/1993
 WO WO-94/18954 A1 9/1994
 WO WO-95/03036 A1 2/1995
 WO WO-96/02247 A1 2/1996
 WO WO-96/29064 A1 9/1996
 WO WO-96/40091 A1 12/1996
 WO WO-96/40829 A1 12/1996
 WO WO-96/41236 A1 12/1996
 WO WO-97/10849 A1 3/1997
 WO WO-97/45105 A1 12/1997
 WO WO-98/14174 A1 4/1998
 WO WO-98/14174 C1 4/1998
 WO WO 98/14175 A1 4/1998
 WO WO-98/43618 A2 10/1998
 WO WO-98/43618 A3 10/1998
 WO WO-98/43618 A9 10/1998
 WO WO 99/00113 A1 1/1999
 WO WO-99/13914 A1 3/1999
 WO WO 00/71079 A2 11/2000
 WO WO 00/71079 A3 11/2000
 WO WO 01/89522 A1 11/2001
 WO WO 02/87545 A1 11/2002
 WO WO-03/96944 A1 11/2003
 WO WO 2004/052401 A2 6/2004
 WO WO 2004/052401 A3 6/2004
 WO WO 2006/089290 A1 8/2006
 WO WO 2007/027819 A2 3/2007
 WO WO 2007/027819 A3 3/2007
 WO WO 2007/027941 A2 3/2007
 WO WO 2007/027941 A3 3/2007
 WO WO 2008/027055 A1 3/2008
 WO WO 2008/057562 A1 5/2008
 WO WO 2008/076373 A1 6/2008
 WO WO 2008/109163 A1 9/2008
 WO WO 2008/137148 A2 11/2008
 WO WO 2008/137148 A3 11/2008
 WO WO 2008/150532 A1 12/2008
 WO WO 2009/126175 A1 10/2009
 WO WO 2009/126401 A1 10/2009
 WO WO 2009/126938 A1 10/2009
 WO WO 2010/068925 A1 6/2010
 WO WO 2010/105172 A1 9/2010
 WO WO 2010/118365 A1 10/2010
 WO WO 2010/121000 A1 10/2010
 WO WO-2011/025838 A1 3/2011
 WO WO-2011/119988 A1 9/2011
 WO WO-2011/123393 A1 10/2011
 WO WO-2011/123395 A1 10/2011
 WO WO-2011/153009 A1 12/2011
 WO WO-2011/153010 A1 12/2011
 WO WO-2011/156119 A1 12/2011
 WO WO-2012/149451 A1 11/2012
 WO WO-2013/090634 A1 6/2013

OTHER PUBLICATIONS

- Bartoli, M.H. et al. (Apr.-Jun. 1990). "In Vitro and In Vivo Antitumoral Activity of Free, and Encapsulated Taxol," *Journal of Microencapsulation* 7(2):191-197.
 Desai, N.P. et al. (Apr. 1994). "Controlled and Targeted Drug Delivery With Biocompatible Protein Shell Microspheres," *The 20th Annual Meeting of the Society for Biomaterials*, Boston, MA, Apr. 5-9, 1994, one page.
 Desai, N.P. et al. (Oct.-Nov. 1994). "Intravenous Targeted Delivery of Chemo-therapeutic Agents in Protein Microspheres," *XIV Interna-*
American BioScience, Inc. v. Baker Norton Pharmaceuticals, Inc. et al., Case No. CV 00-09589 (MRP), before United States District Court for the Central District of California, 2002 U.S. Dist. Lexis 512, Jan. 10, 2002, four pages.
 Pazdur, R. et al. (Oct. 1993). "The Taxoids: Paclitaxel (Taxol) and Docetaxel (Taxotere)," *Cancer Treat. Rev.* 19(4):351-386. (Abstract only, 1 page).
 U.S. Appl. No. 12/331,924, filed on Dec. 10, 2008, for Desai et al.


(56)

References Cited

OTHER PUBLICATIONS

- Groves, M. J. et al. (May 31, 1995). "Introduction," in *Aseptic Pharmaceutical Manufacturing II*, Applications for the 1990s; Chapter 1, edited by M. J. Groves and R. Murty, Interpharm Press, Inc., pp. 1-9.
- Muller, B. G. et al. (Jan. 1996). "Albumin Nanospheres as Carriers for Passive Drug Targeting: An Optimized Manufacturing Technique," *Pharmaceutical Research* 13(1):32-37.
- Verrecchia, T. et al. (Sep. 1995). "Non-Stealth (Poly (Lactic Acid/Albumin)) and Stealth (Poly (Lactic Acid-Polyethylene Glycol)) Nanoparticles as Injectable Drug Carriers," *J. Controlled Release* 36:49-61.
- Non-Final Office Action mailed on Apr. 16, 2009, for U.S. Appl. No. 11/890,197, filed on Aug. 3, 2007, 9 pages.
- Non Final Office Action issued May 12, 2009, for U.S. Appl. No. 11/880,218, filed on Aug. 3, 2007, 11 pages.
- Non-Final Office Action mailed on Jan. 5, 2010 for U.S. Appl. No. 11/890,197, filed on Aug. 3, 2007, 9 pages.
- Non-Final Office Action mailed on Jan. 27, 2010, for U.S. Appl. No. 11/880,218, filed on Jul. 19, 2007, 10 pages.
- Ron, N. et al. (Apr. 2008). "Comparison of Physicochemical Characteristics and Stability of Three Novel Formulations of Paclitaxel: Abraxane, Nanoxel, and Genexol PM," Abstract No. 5622, *presented at 99th AACR Annual Meeting*, San Diego, CA, Apr. 12-16, 2008, located at <http://www.aacrmeetingabstracts.org/cgi/content/meeting_abstract/2008/1_Annual_Meeting/5622?maxtoshow=&hits=10&RESULTFORMAT=1&author1=ron&andorexacttitle=and&andorexacttitleabs=and&searchid=1&FIRSTINDEX=0&sortspec=relevance&fdate=1/1/2004&tdate=12/31/2009&resource-type=HWCIT>, last visited on Sep. 30, 2010, 2 pages.
- Yao, J. H. et al. (Jun. 1, 1993). "Theory and Simulation of Ostwald Ripening," *Phys. Review* 47(21): 14110-14125.
- U.S. Appl. No. 13/038,287, filed Mar. 1, 2011, for Desai et al.
- U.S. Appl. No. 13/073,824, filed Mar. 28, 2011, for Desai et al.
- U.S. Appl. No. 13/073,861, filed Mar. 28, 2011, for Desai et al.
- U.S. Appl. No. 13/133,367, internationally filed Dec. 11, 2009, for Trieu et al.
- U.S. Appl. No. 13/228,323, filed on Sep. 8, 2011, for Desai et al.
- U.S. Appl. No. 13/255,893, internationally filed on Mar. 12, 2010, for Desai et al.
- U.S. Appl. No. 13/263,723, internationally filed on Apr. 9, 2010, for Desai et al.
- Burns, J.L. et al. (1997). "A Light Scattering Study of the Fractal Aggregation Behavior of a Model Colloidal System," *Langmuir* 13(24):6413-6420.
- Kallay, N. et al. (2002). "Stability of Nanodispersions: A Model for Kinetics of Aggregation of Nanoparticles," *Journal of Colloid and Interface Science* 253:70-76.
- Schwarz, C. et al. (1997). "Freeze-Drying of Drug-Free and Drug-Loaded Solid Lipid Nanoparticles (SLN)," *International Journal of Pharmaceutics* 157:171-179.
- U.S. Appl. No. 13/777,980, filed on Feb. 26, 2013, for Desai et al.
- U.S. Appl. No. 13/777,988, filed on Feb. 26, 2013, for Desai et al.
- U.S. Appl. No. 13/776,481, filed on Feb. 25, 2013, for Desai et al.
- U.S. Appl. No. 13/776,484, filed on Feb. 25, 2013, for Desai et al.
- U.S. Appl. No. 13/779,625, filed on Feb. 27, 2013, for Desai et al.
- U.S. Appl. No. 13/781,482, filed on Feb. 28, 2013, for Desai et al.
- U.S. Appl. No. 13/781,479, filed on Feb. 28, 2013, for Desai et al.
- U.S. Appl. No. 13/781,489, filed on Feb. 28, 2013, for Trieu et al.
- U.S. Appl. No. 13/781,487, filed on Feb. 28, 2013, for Tao et al.
- U.S. Appl. No. 13/781,480, filed on Feb. 28, 2013, for Yeo et al.
- U.S. Appl. No. 13/782,990, filed on Mar. 1, 2013, for Desai et al.
- U.S. Appl. No. 13/782,988, filed on Mar. 1, 2013, for Desai et al.
- U.S. Appl. No. 13/782,984, filed on Mar. 1, 2013, for Desai et al.
- U.S. Appl. No. 13/783,122, filed on Mar. 1, 2013, for Desai et al.
- U.S. Appl. No. 13/701,001, filed on May 20, 2011, for Desai et al.
- U.S. Appl. No. 13/782,992, filed on Mar. 1, 2013, for Desai et al.
- U.S. Appl. No. 13/794,705, filed on Mar. 12, 2013, for Desai et al.
- U.S. Appl. No. 13/791,841, filed on Mar. 12, 2013, for Desai et al.
- U.S. Appl. No. 13/794,480, filed on Mar. 12, 2013, for Desai et al.
- U.S. Appl. No. 13/794,486, filed on Mar. 12, 2013, for Heise et al.
- U.S. Appl. No. 13/794,712, filed on Mar. 11, 2013, for Pierce et al.
- U.S. Appl. No. 12/240,893, filed on Sep. 29, 2008, for Desai et al.
- U.S. Appl. No. 12/271,748, filed on Nov. 14, 2008, for Desai et al.
- Stearns, M.E. et al. (Jul. 1, 1992). "Taxol Blocks Processes Essential for Prostate Tumor Cell (PC-3 ML) Invasion and Metastases," *Cancer Search* 52(13): 3776-3781.
- Walter, K.A. et al. (Apr. 15, 1994). "Interstitial Taxol Delivered From a Biodegradable Polymer Implant Against Experimental Malignant Glioma," *Cancer Research* 54:2207-2212.
- Extended European Search Report and European Search Opinion mailed on Jan. 27, 2014, for European Patent Application No. 10011099.8, filed on Jun. 26, 1998, nineteen pages.

* cited by examiner

FIGURE 1

Explore Litigation Insights



Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.